Overall, this study identified BRF2 as a promising cancer target; indicated the molecular changes in the architecture of this protein via binding to TBP; provided the potential hit compounds for this target, followed by examining one of them experimentally, as well as examining new roles for BRF2 in DDR regulation. The gene discussed is BRF2; the disease is cancer.